Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

被引:192
作者
Bode, B. [1 ]
Stenlof, K. [2 ]
Harris, S. [3 ]
Sullivan, D. [4 ]
Fung, A. [4 ]
Usiskin, K. [4 ]
Meininger, G. [4 ]
机构
[1] Atlanta Diabet Associates, Atlanta, GA 30318 USA
[2] Sahlgrens Univ Hosp, Clin Trial Ctr, Gothenburg, Sweden
[3] Univ Western Ontario, Dept Family Med, London, ON, Canada
[4] Janssen Res & Dev LLC, Raritan, NJ USA
关键词
canagliflozin; phase III study; SGLT2; inhibitor; type; 2; diabetes; DOUBLE-BLIND; GLYCEMIC CONTROL; POOLED ANALYSIS; BACKGROUND METFORMIN; ADD-ON; MELLITUS; PLACEBO; SITAGLIPTIN; GLIMEPIRIDE; INHIBITOR;
D O I
10.1111/dom.12428
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: The long-term efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated over 104 weeks in patients aged 55-80 years with type 2 diabetes mellitus (T2DM) inadequately controlled on a stable antihyperglycaemic agent regimen. Methods: In this randomized, double-blind, phase III study, patients received canagliflozin 100 or 300 mg or placebo once daily during a 26-week core period (N=714) and a 78-week extension period (n=624). Efficacy endpoints at week 104 included change from baseline in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG) and systolic blood pressure, and percent change from baseline in body weight and fasting plasma lipids. Safety was assessed by adverse event (AE) reports. Results: At week 104, canagliflozin 100 and 300 mg were associated with reductions in HbA1c versus placebo (-0.32 and -0.43% vs 0.17%, respectively; overall mean baseline, 7.7%) and more patients achieved HbA1c < 7.0% with canagliflozin 100 and 300 mg than with placebo (35.8 and 41.9% vs 20.3%, respectively). Reductions in FPG, body weight and systolic blood pressure, and increases in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were seen with canagliflozin compared with placebo. The overall incidence rates of AEs over 104weeks were 88.0, 89.8 and 86.1% with canagliflozin 100 and 300 mg and placebo, respectively; serious AE rates were low across treatment groups. The incidence rates of urinary tract infections, genital mycotic infections and osmotic diuresis-and volume depletion-related AEs were higher with canagliflozin than with placebo. Conclusion: Canagliflozin improved glycaemic control, reduced body weight and systolic blood pressure, and was generally well tolerated in patients aged 55-80 years with T2DM over 104weeks.
引用
收藏
页码:294 / 303
页数:10
相关论文
共 37 条
[21]   Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies [J].
Nyirjesy, Paul ;
Sobel, Jack D. ;
Fung, Albert ;
Mayer, Cristiana ;
Capuano, George ;
Ways, Kirk ;
Usiskin, Keith .
CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (06) :1109-1119
[22]   Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus [J].
Polidori, David ;
Sha, Sue ;
Ghosh, Atalanta ;
Plum-Moerschel, Leona ;
Heise, Tim ;
Rothenberg, Paul .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (05) :E867-E871
[23]   Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial [J].
Ridderstrale, Martin ;
Andersen, Knut Robert ;
Zeller, Cordula ;
Kim, Gabriel ;
Woerle, Hans J. ;
Broedl, Uli C. .
LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (09) :691-700
[24]   Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy [J].
Rosenstock, Julio ;
Vico, Marisa ;
Wei, Li ;
Salsali, Afshin ;
List, James F. .
DIABETES CARE, 2012, 35 (07) :1473-1478
[25]   Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes [J].
Rosenstock, Julio ;
Aggarwal, Naresh ;
Polidori, David ;
Zhao, Yue ;
Arbit, Deborah ;
Usiskin, Keith ;
Capuano, George ;
Canovatchel, William .
DIABETES CARE, 2012, 35 (06) :1232-1238
[26]   Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial [J].
Schernthaner, Guntram ;
Gross, Jorge L. ;
Rosenstock, Julio ;
Guarisco, Michael ;
Fu, Min ;
Yee, Jacqueline ;
Kawaguchi, Masato ;
Canovatchel, William ;
Meininger, Gary .
DIABETES CARE, 2013, 36 (09) :2508-2515
[27]   Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study [J].
Seck, T. ;
Nauck, M. ;
Sheng, D. ;
Sunga, S. ;
Davies, M. J. ;
Stein, P. P. ;
Kaufman, K. D. ;
Amatruda, J. M. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) :562-576
[28]   Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects [J].
Sha, S. ;
Devineni, D. ;
Ghosh, A. ;
Polidori, D. ;
Chien, S. ;
Wexler, D. ;
Shalayda, K. ;
Demarest, K. ;
Rothenberg, P. .
DIABETES OBESITY & METABOLISM, 2011, 13 (07) :669-672
[29]   Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies [J].
Sinclair, Alan ;
Bode, Bruce ;
Harris, Stewart ;
Vijapurkar, Ujjwala ;
Mayer, Cristiana ;
Fung, Albert ;
Shaw, Wayne ;
Usiskin, Keith ;
Desai, Mehul ;
Meininger, Gary .
BMC ENDOCRINE DISORDERS, 2014, 14
[30]   Diabetes Mellitus in Older People: Position Statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes [J].
Sinclair, Alan ;
Morley, John E. ;
Rodriguez-Manas, Leo ;
Paolisso, Giuseppe ;
Bayer, Tony ;
Zeyfang, Andrej ;
Bourdel-Marchasson, Isabelle ;
Vischer, Ulrich ;
Woo, Jean ;
Chapman, Ian ;
Dunning, Trisha ;
Meneilly, Graydon ;
Rodriguez-Saldana, Joel ;
Gutierrez Robledo, Luis Miguel ;
Cukierman-Yaffe, Tali ;
Gadsby, Roger ;
Schernthaner, Guntram ;
Lorig, Kate .
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2012, 13 (06) :497-502